A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.
Type of Study: Clinical Trial
Sponsor / Support: Breast International Group (BIG), Alliance Foundation Trials (AFT), Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU), Frontier Science Foundation, Roche
Primary Objectives: To evaluate the efficacy of adjuvant Atezolizumab + T-AC/EC compared with T-AC/EC alone in patients with TNBC
Design: This is a randomized clinical trial for triple-negative breast cancer patients who underwent surgical treatment and assesses whether the inclusion of ATEZOLIZUMAB (immunotherapy) is likely to increase the chances of cure.
Sample Size: 2.300 patients
Principal Investigator: Gustavo Werutsky (Steering Committee – LACOG)
Countries LATAM: Brazil and Mexico

Ongoing studies
Breast
GBECAM 0115 – AMAZONA III
LACOG 0115 – LORELEI
LACOG 0413 – Male Breast Cancer
LACOG 0615 – LATINABreast
LACOG 2118 – ALEXANDRA/IMpassion 030
PALLAS
Gastro-Intestinal
LACOG/GTG 1318 – CCA
LACOG 0119
Gynecological
LACOG 0215 – EVITA
LACOG 1018 – PALBO in Ovarian Cancer
Genitourinary
LACOG 1518 – Bladder Cancer Registry
LACOG 0515 – Testicular Registry
LACOG 0217 – IRONMAN
LACOG 1818 – Prostate Cancer Registry
LACOG 0218 – Hercules
LACOG 0415 – APA in Prostate Cancer
LACOG 0519 – PEACE III
Lung
LACOG 0116 – LATINO LUNG
LACOG 0118 – RELANCE
LACOG 0417 – CNS MTX
LACOG 1918
LACOG 0718 – PCI Project
LACOG 2218 – PACIFIC BRAZIL
Neuro
LACOG 0619